Our results clearly showed the antitumor activity of MLN2238 in a variety of mouse models of B-cell lymphoma and PCM, supporting its clinical development. MLN9708 is being evaluated in multiple phase I and I/II trials.
Clinical cancer research : an official journal of the American Association for Cancer Research
Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA. Edmund.Lee [at] Roche.com
Clin Cancer Res. 2011 Dec;17(23):7313-23
© Galenicom 1999-2013